Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone44-80-8189-6257
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees111
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions
What is Kiniksa Pharmaceuticals' stock symbol?
Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."
How were Kiniksa Pharmaceuticals' earnings last quarter?
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.71) by $0.03. View Kiniksa Pharmaceuticals' Earnings History.
When is Kiniksa Pharmaceuticals' next earnings date?
What price target have analysts set for KNSA?
3 Wall Street analysts have issued 12-month target prices for Kiniksa Pharmaceuticals' shares. Their forecasts range from $26.00 to $35.00. On average, they expect Kiniksa Pharmaceuticals' stock price to reach $31.3333 in the next year. This suggests a possible upside of 239.8% from the stock's current price. View Analyst Price Targets for Kiniksa Pharmaceuticals.
What is the consensus analysts' recommendation for Kiniksa Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kiniksa Pharmaceuticals.
What are Wall Street analysts saying about Kiniksa Pharmaceuticals stock?
Here are some recent quotes from research analysts about Kiniksa Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts, United States. " (8/16/2019)
- 2. Wedbush analysts commented, "Our estimated market value of the firm is $1.75B, which includes the asset value for tagraxofusp and 15% discount rate and 2% terminal growth rate. The probability of success is 66% for tagraxofusp in indications beyond BPDCN and 45% for SL-701. Assuming roughly 50.1M shares outstanding at the end of 2Q20, this leads to a 12-month price target of approximately $35 per share." (8/14/2019)
Has Kiniksa Pharmaceuticals been receiving favorable news coverage?
News articles about KNSA stock have trended negative on Friday, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kiniksa Pharmaceuticals earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Kiniksa Pharmaceuticals.
Who are some of Kiniksa Pharmaceuticals' key competitors?
Some companies that are related to Kiniksa Pharmaceuticals include Zogenix (ZGNX), Ligand Pharmaceuticals (LGND), Deciphera Pharmaceuticals (DCPH), Uniqure (QURE), Prestige Consumer Healthcare (PBH), Eidos Therapeutics (EIDX), Insmed (INSM), Nabriva Therapeutics (NBRV), Tricida (TCDA), Apellis Pharmaceuticals (APLS), Heron Therapeutics (HRTX), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX), Alder Biopharmaceuticals (ALDR) and Madrigal Pharmaceuticals (MDGL).
What other stocks do shareholders of Kiniksa Pharmaceuticals own?
Who are Kiniksa Pharmaceuticals' key executives?
Kiniksa Pharmaceuticals' management team includes the folowing people:
- Mr. Sanj K. Patel, CEO & Chairman (Age 49)
- Mr. Stephen Mahoney, Pres & COO (Age 47)
- Dr. John F. Paolini, Chief Medical Officer (Age 53)
- Mr. Chris Heberlig, Exec. VP & CFO (Age 43)
- Mark Ragosa C.F.A., VP of Investor Relations
When did Kiniksa Pharmaceuticals IPO?
(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Kiniksa Pharmaceuticals' major shareholders?
Kiniksa Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.27%), BlackRock Inc. (2.02%), VHCP Management II LLC (1.11%), Citadel Advisors LLC (0.68%), VHCP Management III LLC (0.57%) and Northern Trust Corp (0.28%). Company insiders that own Kiniksa Pharmaceuticals stock include Bros Advisors Lp Baker, Cormorant Asset Management, Lp and James E Flynn. View Institutional Ownership Trends for Kiniksa Pharmaceuticals.
Which institutional investors are selling Kiniksa Pharmaceuticals stock?
KNSA stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., VHCP Management II LLC, VHCP Management III LLC, Victory Capital Management Inc., Wells Fargo & Company MN, Alps Advisors Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Kiniksa Pharmaceuticals.
Which institutional investors are buying Kiniksa Pharmaceuticals stock?
KNSA stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, BlackRock Inc., Point72 Asset Management L.P., First Manhattan Co., Northern Trust Corp, Morgan Stanley, Swiss National Bank and Charles Schwab Investment Management Inc.. Company insiders that have bought Kiniksa Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Cormorant Asset Management, Lp and James E Flynn. View Insider Buying and Selling for Kiniksa Pharmaceuticals.
How do I buy shares of Kiniksa Pharmaceuticals?
Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Kiniksa Pharmaceuticals' stock price today?
One share of KNSA stock can currently be purchased for approximately $9.22.
How big of a company is Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals has a market capitalization of $505.76 million. The company earns $-103,230,000.00 in net income (profit) each year or ($3.49) on an earnings per share basis. Kiniksa Pharmaceuticals employs 111 workers across the globe.View Additional Information About Kiniksa Pharmaceuticals.
What is Kiniksa Pharmaceuticals' official website?
How can I contact Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 44-80-8189-6257 or via email at [email protected]
MarketBeat Community Rating for Kiniksa Pharmaceuticals (NASDAQ KNSA)
MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote "Outperform" if you believe KNSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
